Pain after extracorporeal shock wave lithotripsy (ESWL), a non-surgical procedure used to treat kidney stones, is common and is usually treated with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. However, NSAIDs may cause side effects in some patients, including stomach irritation and kidney problems.
Palmitoylethanolamide (PEA) is a naturally occurring substance in the body with anti-inflammatory and pain-relieving properties and has been shown to be safe in previous studies. This study aims to compare the effectiveness of PEA with ibuprofen for controlling acute postoperative pain after ESWL.
Participants undergoing ESWL will be randomly assigned to receive either oral PEA or oral ibuprofen. Pain intensity will be measured using a visual analogue scale during the first 24 hours after the procedure. The use of rescue pain medication and any side effects will also be recorded.
The results of this study may help determine whether PEA can be an effective alternative to ibuprofen for the management of acute pain after ESWL.

开始日期2026-01-01

申办/合作机构

Benha University

CTRI/2025/11/098050

/ Not yet recruitingN/A

Effect of combination of PEA and acetyl carnitine as an adjunct therapy for periarthritis shoulder. a randomized controlled trial - NIL

开始日期2025-12-21

申办/合作机构-

NCT07489118

/ Active, not recruitingN/AIIT

Impact of Consuming Protein and Polyphenol Bars on Metabolic Health

The goal of this clinical trial is to learn if pulse (pea) protein works similar to animal (whey) protein in protein bars consumed by healthy adults.
The main questions it aims to answer are: What are the differences in taste and tolerance profiles between pea and whey proteins? What metabolic and immune changes do participants experience while eating them? What gastrointestinal microbiome shifts can be observed in these participants? How incorporation and complexation of polyphenols with these proteins changes the study outcomes?
Participants will: Consume 1 protein bar with whey protein, pea protein, pea protein with complexed polyphenols, or pea protein with free polyphenols every day for 2 months. Visit the study site at baseline and end of study for checkups and tests. Fill dietary, food acceptance, gastrointestinal tolerance, and global health questionnaires.

开始日期2025-05-01

申办/合作机构

North Carolina State University

100 项与帕米醇相关的临床结果

登录后查看更多信息

100 项与帕米醇相关的转化医学

登录后查看更多信息

100 项与帕米醇相关的专利（医药）

登录后查看更多信息

2,502

项与帕米醇相关的文献（医药）

2026-05-01·SLEEP MEDICINE

Obstructive sleep apnea and echocardiographic indicators of elevated pulmonary hypertension probability after pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension

Article

作者: Çınar, Caner ; Balcan, Baran ; Yıldızeli, Bedrettin ; Ataş, Halil ; Yıldızeli, Şehnaz Olgun ; Mutlu, Bülent ; Peker, Yüksel

STUDY OBJECTIVES:

We previously demonstrated that 80% of patients with chronic thromboembolic pulmonary hypertension (CTEPH) exhibit sleep-related breathing disorders (SBDs), primarily obstructive sleep apnea (OSA), followed by isolated sleep-related hypoxemia (ISRH). In this follow-up study, we aimed to assess the distribution of SBDs and predictors of echocardiography-based residual pulmonary hypertension (PH) risk after pulmonary endarterectomy (PEA) in the same cohort.

METHODS:

Overnight polysomnography and echocardiography were performed in 24 CTEPH patients approximately 112 ± 65 days after PEA. Residual PH risk was defined as peak tricuspid regurgitation velocity (TRV) > 2.8 m/s and systolic pulmonary artery pressure (SPAP) ≥ 30 mmHg.

RESULTS:

In the overall cohort, PEA significantly reduced TRV (from 3.7 ± 0.9 to 2.5 ± 0.9 m/s, p < 0.001) and SPAP (58.3 ± 26.9 to 29.8 ± 17.7 mmHg, p < 0.001). Among six patients with preoperative ISRH, two improved, while four developed OSA postoperatively. Of the 16 patients with preoperative OSA, 14 remained in the same category after surgery. Residual PH risk was observed in 13 patients (54.2%), all of whom had OSA, while no residual PH risk was detected in patients without SBDs (p = 0.003). In multivariate logistic regression, postoperative apnea-hypopnea index was independently associated with echo-based residual PH risk (odds ratio 1.19; 95% CI 1.02-1.38; p = 0.025), after adjustment for age, sex, body mass index, and baseline mean pulmonary arterial pressure.

CONCLUSIONS:

PEA improves pulmonary hemodynamics and resolves ISRH in some patients with CTEPH. However, residual PH risk remains frequent and is independently associated with OSA severity. These findings emphasize the importance of systematic screening, early diagnosis, and management of OSA to potentially mitigate residual PH risk and improve postoperative outcomes in CTEPH.

2026-05-01·EXPERIMENTAL NEUROLOGY

Palmitoylethanolamide ameliorates postoperative cognitive dysfunction via microglial PPARα-mediated anti-inflammatory and neuroprotective mechanisms

Article

作者: Wu, Wensi ; Liu, Guijie ; Li, Liang ; Li, Dongliang ; Zheng, Zhenzhen ; Zhang, Xiaojun

BACKGROUND:

Postoperative cognitive dysfunction (POCD) is a frequent neurological complication characterized by memory and learning impairments in the elderly, while effective pharmacological interventions remain limited. Palmitoylethanolamide (PEA), an endogenous lipid mediator with anti-inflammatory and neuroprotective properties, has emerged as a potential therapeutic candidate.

METHODS:

An aged mouse model of POCD was used to evaluate the effects of PEA. Cognitive performance was assessed by the open field test, novel object recognition, and Barnes maze. Neuroinflammation, microglial activation, neuronal integrity, and synaptic plasticity-related proteins were assessed using immunostaining and molecular analyses both in vivo and in vitro. To determine the role of peroxisome proliferator-activated receptor-α (PPARα), stereotaxic delivery of shPPARα virus to prefrontal cortex (PFC) microglia was performed.

RESULTS:

PEA treatment significantly improved both short- and long-term memory in aged POCD mice. Mechanistically, PEA attenuated microglial activation, shifted microglial activation toward the anti-inflammatory phenotype, preserved neuronal survival, and upregulated synaptic plasticity-associated proteins. Importantly, PEA restored PPARα activity, and knockdown of PPARα abolished these protective effects both in vivo and in vitro, confirming its essential role.

CONCLUSIONS:

PEA alleviates cognitive deficits in aged POCD mice by enhancing PPARα signaling, reducing neuroinflammation, and promoting neuronal protection. These findings support PEA as a promising therapeutic strategy for the treatment of aged POCD.

2026-04-01·PAIN

The contribution of baseline circulating endocannabinoids to individual differences in human pain sensitivity: a quantitative sensory testing study

Article

作者: Cormie, M.A. ; Moayedi, M. ; Finn, D.P. ; Tomin, R. ; Sexton, C. ; Kyeremaa-Adjei, C. ; Bourke, S.L. ; Honigman, L. ; Mohabir, N. ; Murray, K.B. ; Abssy, S.S. ; Atlas, L.Y. ; Fatemi, S.A. ; Boileau, I.

Abstract:

The endocannabinoid (eCB) system comprises cannabinoid receptors; endogenous ligands, including anandamide (AEA), 2-arachidonoylglycerol (2-AG); and related N -acylethanolamines (NAEs), N- palmitoylethanolamide (PEA), and N- oleoylethanolamide (OEA); and metabolizing enzymes (eg, fatty acid amide hydrolase [FAAH]). The eCB system modulates nociceptive circuits in rodents. In humans, the FAAH C385A polymorphism is associated with reduced pain sensitivity, suggesting eCB tone contributes to individual pain differences, but this has yet to be tested. Here, we determined whether the eCB system is associated with somatosensory and pain sensitivity measured with quantitative sensory testing (QST) in 91 healthy participants (39 males, 52 females). We tested 3 hypotheses: (1) FAAH C385A polymorphism, cannabis use, and sex affect serum eCB/NAE concentrations; (2) FAAH C385A carriers show altered pain sensitivity vs noncarriers; and (3) baseline serum eCB/NAE concentrations are associated with QST measures. eCB/NAE concentrations were not statistically different based on sex ( P > 0.05), FAAH genotype ( P > 0.05), or cannabis use ( P > 0.05). To address collinearity of AEA, OEA, and PEA, we performed a principal components analysis, which identified a single component of FAAH substrates. Linear regressions found that FAAH genotype did not affect QST measures and that baseline 2-AG and FAAH substrate concentrations were not associated with QST measures, except pressure pain thresholds (PPT; P = 0.003), which were associated with AEA and OEA. Baseline eCB/NAE levels and FAAH genotype are not associated with the outcome measures of standard QST tests that rely on point estimates in healthy adult humans; nonetheless, circulating FAAH substrate levels were associated with PPT.

136

项与帕米醇相关的新闻（医药）

2026-03-10

·BioSpace

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease). This novel therapy integrates Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), provided through its collaboration with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC). The patent publication highlights the potential of this MEAI-PEA combination to offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges: obesity, affecting over 890 million adults worldwide, and MASLD, impacting approximately 30% of the global adult population. Moreover, due to the presumed mechanism of action of the combination, this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD. "The publication of this international patent is part of our mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. "By combining our MEAI platform with PEA from our partners at NeuroThera Labs, we are positioning ourselves to address the escalating demand for effective, tolerable and safe treatments in the obesity and liver health space. This comes at a time when the global weight loss drugs market is experiencing rapid growth, which was valued at approximately $37 billion in 2025 and is forecasted to reach $226 billion by 2035 , driven by increasing awareness of obesity as a chronic disease and the need for innovative alternatives to GLP-1 agonists." About Clearmind Medicine Inc. Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND". For further information, visit: or contact: Investor Relations invest@clearmindmedicine.com Telephone: (604) 260-1566 US: CMND@crescendo-ir.com General Inquiries Info@Clearmindmedicine.com Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of this MEAI-PEA combination to offer a safe, non-hallucinogenic neuroplastogen treatment for obesity and MASLD, its mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions, how this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD, how it is position itself to address the escalating demand for effective, tolerable treatments in the obesity and liver health space and the expected growth of the global weight loss drugs market. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

2026-03-02

·PRNewswire

Decentralized Clinical Trial Validates Novel "Fasting Mimetic" Formulation for Cardiometabolic Health

Peer-reviewed randomized controlled study by People Science and Mimio Health, published in Nature Scientific Reports LOS ANGELES, March 2, 2026 /PRNewswire/ -- People Science today announced the publication of a randomized, double-blind, placebo-controlled clinical trial conducted with Mimio Health in Nature Scientific Reports, marking an important step forward in the scientific exploration of nutrient-sensing metabolic biology. Continue Reading Scientific Reports, Mimio publication Fasting Mimetics, FIrst page The study evaluated a novel daily supplement formulation designed to selectively activate biological pathways associated with fasting—such as autophagy and metabolic repair—without requiring dietary restriction. Rather than attempting to replicate fasting behaviorally, the formulation targets underlying molecular signals using a proprietary blend of biomolecules, including spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide (OEA). Over eight weeks, the intervention produced statistically significant improvements in multiple cardiometabolic biomarkers compared with placebo, including Total Cholesterol, LDL, Oxidized LDL, and Fasting Glucose. Participants receiving the active formulation also reported greater satiety, indicating improved appetite regulation in an older population with elevated metabolic risk. The supplement was shown to be safe and well-tolerated for daily use. Taken together, the findings provide clinical evidence that components of fasting biology can be engaged through targeted nutritional intervention—opening new possibilities for studying and refining metabolic repair pathways in populations for whom fasting is impractical or contraindicated. "Validating a metabolic intervention like this typically requires a controlled clinical setting, but we wanted to prove efficacy in the real world," said Dr. Chris Rhodes, PhD, CEO of Mimio Health. "People Science allowed us to conduct a rigorous, gold-standard trial directly in participants' homes. The data we gathered not only confirmed our mechanism of action but showed that our formulation can deliver the benefits of fasting to the population that needs it most." Study Highlights Design: Randomized, double-blind, placebo-controlled, decentralized clinical trial (RCT). Duration: 8 weeks. Participants: 42 adults (Average age 62 ± 4 years) with elevated BMI and HbA1c were recruited, with high retention rates. Endpoints: Biological: Comprehensive metabolic blood panels (Lipids, Glucose, Inflammation). Subjective: Appetite and Satiety (Visual Analog Scale), Energy levels. Safety: Comprehensive metabolic panel and adverse event monitoring. Results: Significant reductions in Total Cholesterol, LDL, Oxidized LDL, and Fasting Glucose vs. placebo. 91% of participants in the active group reported improved mealtime appetite regulation (vs. 47% in placebo). Confirmed safety and tolerability for daily use. Full publication: Nature Scientific Reports (DOI: 10.1038/s41598-026-38495-7) Enabling the Next Phase of Metabolic Research Beyond the biological outcomes, the study highlights the growing role of decentralized clinical trials in advancing complex metabolic science. Using People Science's Chloe platform, the trial successfully conducted remote biosampling, daily-dosing adherence, and biomarker analysis entirely in participants' homes, demonstrating that high-fidelity clinical research can be conducted outside traditional research centers without compromising rigor. "This work shows that we can investigate sophisticated biological mechanisms in real-world conditions and still meet the highest scientific standards," said Dr. Noah Craft, MD, PhD, Co-CEO of People Science. "By combining decentralized infrastructure with biomarker-driven endpoints, we're able to move more quickly from hypothesis to evidence, and, importantly, to identify where the science should go next." The publication establishes a clinically validated starting point for future investigations into fasting-associated biology, including longer-term studies, mechanistic refinement, and exploration across additional metabolic populations. Rather than serving as a conclusion, the findings signal the emergence of a more precise, accessible approach to studying metabolic resilience and repair. About People Science People Science is a technology-enabled clinical research organization pioneering the next generation of decentralized trials. Its proprietary platform, Chloe, enables rapid, scalable, and scientifically rigorous studies for innovators in consumer health and wellness. Learn more: . About Mimio Health Mimio Health is a nutritechnology company dedicated to decoding human biology to enhance healthspan. Their flagship formulation was developed to mimic the cellular and metabolic benefits of 36-hour fasting, making the benefits of regenerative biology accessible to everyone without the difficulty of fasting. Learn more at . Press Contact [email protected] SOURCE People Science, Inc. 21% more press release views with Request a Demo

临床结果

2026-03-02

·PRNewswire

Mimio Health Announces Breakthrough Clinical Trial Of Its Fasting Mimetic, Demonstrating Fasting-Like Benefits Without Dietary Changes

The study found that taking Mimio ™ significantly improved key markers of cardiometabolic health, appetite regulation, digestive comfort, and cellular stress compared to placebo. SAN FRANCISCO, March 2, 2026 /PRNewswire/ -- Mimio Health, an award-winning nutraceutical company developing biomimetic products designed from human biology to optimize cellular function, boost performance, and support longevity, today announced the publication of a randomized, double-blind placebo-controlled clinical study in Nature Scientific Reports demonstrating that its flagship fasting mimetic supplement delivers significant fasting-like benefits without requiring dietary restriction or lifestyle changes. Continue Reading Mimio Biomimetic Cell Care Starter Kit The peer-reviewed study provides clinical validation of Mimio's biomimetic research approach, which mapped the molecular changes in the human body during a 36-hour fast to recreate the cellular, metabolic, and longevity benefits of prolonged fasting through daily supplementation. Mimio's formulation, utilizing a patented blend of human bioactives highly elevated during a 36-hour fast—spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide (OEA), activates the same beneficial cellular pathways as fasting, without needing to fast. Study Design and Key Findings The eight-week clinical trial was conducted in partnership with People Science, an independent decentralized clinical research organization, and enrolled healthy adults with elevated cardiometabolic risk factors. Study Overview Design: Randomized, double-blind, placebo-controlled decentralized clinical trial Duration: 8 weeks Participants: 42 adults (average age 62 ± 4 years) with elevated BMI and HbA1c, with high retention rates Endpoints: Biological: Comprehensive metabolic blood panels (lipids, glucose, inflammatory markers) Subjective: Appetite and satiety (Visual Analog Scale), energy levels Safety: Comprehensive metabolic panels and adverse event monitoring Key Results Statistically significant reductions in total cholesterol, LDL cholesterol, LDL particle number, Non-HDL Cholesterol, Oxidative Stress, and Fasting Glucose versus placebo 91% of participants in the Mimio group reported improved appetite regulation including significantly reduced daily hunger levels, food noise, distraction from cravings, and mealtime appetite, and improved satiety vs the placebo group The formulation was confirmed to be well tolerated for daily use and significantly reduced reports of bloating and digestive discomfort vs the placebo group. Full Publication: Nature Scientific Reports (DOI: 10.1038/s41598-026-38495-7) "These findings demonstrate, in a gold-standard placebo-controlled trial, that Mimio's fasting mimetic formulation can deliver similar metabolic, cellular, and appetite-regulating benefits as fasting – without fasting," said Dr. Chris Rhodes, PhD, CEO and Co-Founder of Mimio Health. "We observed significant improvements in cholesterol and glucose metabolism, oxidative stress, digestion, and hunger control that mimicked our previous findings of the benefits of a 36-hour fast, without requiring participants to change how they eat or live." This trial builds on prior human research Mimio Health conducted with UC Davis and Mount Sinai showing the formula's ability to support improvements to cellular health, metabolic function, and biological aging. Their expanding body of evidence supports Mimio's mission to extend healthspan by decoding and recreating our body's natural regenerative systems. Beyond their fasting mimetic, Mimio Health is applying its biomimetic research framework to develop additional formulations designed to replicate the benefits of other longevity-associated states, such as exercise, sleep and meditation, in simple on-demand formats. About Mimio Health Mimio Health is a nutritechnology company dedicated to decoding human biology to unlock the body's natural regenerative power on demand. Its flagship fasting mimetic formulation is designed to mimic the cellular and metabolic benefits of a 36-hour fast—without needing to fast. Learn more at . About People Science People Science is a technology-enabled clinical research organization pioneering the next generation of decentralized trials. Its proprietary platform, Chloe, enables rapid, scalable, and scientifically rigorous studies for innovators in consumer health and wellness. Learn more at . Media Contact Alissa Marinello [email protected] SOURCE Mimio Health, Inc. 21% more press release views with Request a Demo

临床结果

100 项与帕米醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08328	帕米醇	J	DB14043

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
呼吸道感染	-	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肌肉骨骼疼痛	临床2期	美国	Quantum BioPharma Ltd.	2023-01-19
慢性肌肉骨骼疼痛	临床2期	加拿大	Quantum BioPharma Ltd.	2023-01-19
慢性疼痛	临床2期	美国	Quantum BioPharma Ltd.	2023-01-19
慢性疼痛	临床2期	加拿大	Quantum BioPharma Ltd.	2023-01-19
中链酰基辅酶A脱氢酶缺乏症	临床2期	美国	Quantum BioPharma Ltd.	2023-01-19
中链酰基辅酶A脱氢酶缺乏症	临床2期	加拿大	Quantum BioPharma Ltd.	2023-01-19
特发性肥大细胞活化综合征	临床2期	美国	Quantum BioPharma Ltd.	2023-01-19
特发性肥大细胞活化综合征	临床2期	加拿大	Quantum BioPharma Ltd.	2023-01-19
新型冠状病毒感染	临床2期	美国	Quantum BioPharma Ltd.	2020-12-14
Tourette 综合征	临床2期	美国	SciSparc Ltd.	2017-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05246670 (CTgov)	临床2期	化疗引起的损伤 \| 恶性实体肿瘤 \| 血液肿瘤 ... 更多	88	Quality-of-Life Assessment+Palmidrol (Lower-dose PEA)	襯製顧窪積膚憲願壓蓋(蓋憲遞獵窪顧繭構觸窪) = 選淵構齋膚鏇廠製窪鑰選鹹糧觸願壓網簾簾遞 (憲壓積糧積鹹願簾鹹積, 5.42) 更多	-	2025-01-24
				Quality-of-Life Assessment+Palmidrol (Higher-dose PEA)	襯製顧窪積膚憲願壓蓋(蓋憲遞獵窪顧繭構觸窪) = 鏇憲範顧壓積醖蓋夢構選鹹糧觸願壓網簾簾遞 (憲壓積糧積鹹願簾鹹積, 12.24) 更多
NCT03066193 (CTgov)	临床2期	Tourette 综合征	17	Palmitoylethanolamide+Dronabinol	夢鑰鹽獵餘築襯艱範壓(廠膚膚遞顧構選鏇遞襯) = 壓獵艱願齋艱鬱醖窪鹹繭獵艱廠網壓襯製獵鹹 (鏇艱糧遞夢範築糧觸顧, 襯構選觸糧蓋餘網夢鏇 ~ 網範築淵網憲積獵餘膚) 更多	-	2019-12-19
ISRCTN72647928 (Pubmed \| Invest Ophthalmol Vis Sci)	N/A	高血压	40	Palmitoylethanolamide 300 mg	製窪繭廠淵艱遞積鹽夢(壓鹽糧壓積範繭淵鹽鹽) = 鹽醖願選觸鹹鬱壓獵醖構餘築網簾壓醖蓋鏇鑰 (遞網積齋窪鑰鹹蓋鑰膚 ) 更多	积极	2013-02-01
				Placebo	製窪繭廠淵艱遞積鹽夢(壓鹽糧壓積範繭淵鹽鹽) = 蓋顧蓋構艱簾構鏇鏇艱構餘築網簾壓醖蓋鏇鑰 (遞網積齋窪鑰鹹蓋鑰膚 ) 更多
ISRCTN72647928 (ARVO2012)	N/A	高血压	40	Palmitoylethanolamide	鬱餘糧網夢製觸獵蓋範(鏇觸築夢願膚築鹹廠齋) = no side effects during the treatment period were observed 網簾鏇餘襯觸築鹹繭鏇 (齋糧醖衊鑰蓋蓋選築觸 )	-	2012-03-01
				Placebo